Advertisement

Determination of the Antiinfectious Activity of RU 41740 (Biostim) as an Example of an Immunomodulator

  • I. Ounis
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 319)

Keywords

Cystic Fibrosis Alveolar Macrophage Klebsiella Pneumoniae Immune Deficiency Niflumic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. Alfetra, A. Amoroso, G. M. Ferri, P. Basso, G. Guide, L. Bonomo, In vivo effects of RU41740 in aged humans: evaluation of some immunological parameters, Immunol. Clin. 7:39–45 (1988).Google Scholar
  2. 2.
    J. P. Andreux, M. Renard, and M. H. Andreux, Modulation of murine hemopoiesis by repeated injection of glycoprotein extract from klebsiella pneumoniae, Int. J. Immunopharmacol. 8:147–154 (1986).PubMedCrossRefGoogle Scholar
  3. 3.
    D. Anthoine, B. Blaive, G. Cabanieu, J. Chretien, A. Danrigal, C. H. Ducreuzet, D. Dusser, P. Leophonte, J. Migueres, J. F. Muir, and C. H. Ollagnier, Etude en double aveugle du Biostim dans la prevention des surinfections des patients atteints de bronchopathie chronique, Rev. Pneumol. Clin. 413:213–217 (1985).PubMedGoogle Scholar
  4. 4.
    M. D. Anthonisen, M. D. Manfreda, C. P. W. Warren, E. S. Hershfield, G. K. M. Harding, and N. A. Nelson, Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease, Ann. Intern. Med. 106:193–204 (1987).Google Scholar
  5. 5.
    D. M. Bamberger and B. L. Herndon, Bactericidal capacity of neutrophils in rabbits with experimental acute and chronic abscesses, J. Infect. Dis. 162:186–192, 1990.PubMedCrossRefGoogle Scholar
  6. 6.
    H. Blomgren, H. Viland, B. Cedermark, T. Theve, and U. Ohman, Oral treatment with RU41740 (Biostim) in patients with advanced colorectal cancer: influence on the blood lymphocyte population, Int. J. Immunopharmac. 2:71–76, 1989.CrossRefGoogle Scholar
  7. 7.
    J. Bonde, R. Dahl, R. Edeltein, A. Kok-Jensen, L. Lazer, L. PUnakivi, A. Seppala, U. Soes-Petersen, and K. Viskum, The effect of RU 41740 an immune modulating compound in the prevention of acute exacerbations in patients with chronic bronchitis, Eur. J. Respir. Dis. 69:235–241 (1986).PubMedGoogle Scholar
  8. 8.
    P. Bonfils, Prophylaxie des infections des voies respiratoires chez l’enfant par le RU41740, Presse Med., 17:1430–1432 (1988).Google Scholar
  9. 9.
    C. Brambilla, Infections respiratoires recidivantes: definition des populations a risque et criteres d’evaluation dans les etudes d’efficacite de la prophylaxie, M/S, suppl. n°7:19–24 (1990).Google Scholar
  10. 10.
    F. Capsoni, F. Minonzio, E. Venegoni, A. M. Ongari, G. Guide and C. Zanussi, In vitro modulation of polymorphonuclear leukocyte functions by a glycoprotein extract from klebsiella pneumoniae (RU 41740): correction of corticosteroid-induced defects and phagocytosis and adherence, Int. J. Immunotherapy. IV 2: 107–115 (1988).Google Scholar
  11. 11.
    F. Capsoni, F. Minonzio, E. Venegoni, A. M. Ongari, P. L. Meroni, G. Guide, and C. Zanussi, In vitro and ex vivo effect of RU41740 on human polymorphonuclear leukeocyte fonction, Int. J. Immuno. 10:121–133 (1988).CrossRefGoogle Scholar
  12. 12.
    P. Carles, F. Fournial, R. Bollinelli, Interet du Biostim dans la prevention des episodes de surinfection chez les insuffisants respiratoires par bronchite chronique ou dilation des bronches, Gaz Med. France. 8825:1–3 (1981).Google Scholar
  13. 13.
    B. Chaumet, M. and Ch. Boissier, Structure et distribution du RU 41740, Presse Med. 17:1423–1425 (1988).PubMedGoogle Scholar
  14. 14.
    N. V. Christou, I. Zakaluzny, J. C. Marshall, and C. W. Nohr, The effect of the immunomodulator RU 41740 (Biostim) on the specific and nonspecific immunosuppression induced by thermal injury of protein deprivation, Arch. Surg. 123:207–210 (1988).PubMedCrossRefGoogle Scholar
  15. 15.
    J. P. Devlin and K. D. Hargrave, The design and synthesis of immune regulatory agents: targets and approaches. Tetrahedron 14:4327–4369 (1989).CrossRefGoogle Scholar
  16. 16.
    A. Fietta, C. Bersani, V. De Rose, A. Grassi, P. Mangiarotti, M. Uccelli, and C. Grassi, Evaluation of systemic host defense mechanisms in chronic bronchitis. Respiration 53:37–43 (1988).PubMedCrossRefGoogle Scholar
  17. 17.
    A. Fietta, C. Bersani, V. De Rose, P. Mangiarotti, C. Merlini, M. Uccelli, G. Guidi, G. Gialdroni Grassi, Double-blind trial RU 41740 vs. placebo: immunological and clinical effects in a group of patients with chronic bronchitis. Respiration 54:145–152 (1988)PubMedCrossRefGoogle Scholar
  18. 18.
    Fiszer-Szafarz, M. Rommain, C. Brossard, and P. Smets, Hyaluronic acid-degrading enzymes in rat alveolar macrophagesand in alveolar fluid: stimulation of enzyme activity after oral treatment with the immunomodulator RU 41740. Biology of the Cell 63: 355–360 (1988).PubMedGoogle Scholar
  19. 19.
    M. Fortier, A. Bonfils, R. Zalisz, M. Heyman, and P. Smets, Pharmacokinetic profile of RU 41740, a bacterial immunomodulator, in mice, rats, and monkeys. Internatl. J. of Phamaceutics. 52:27–36 (1989).CrossRefGoogle Scholar
  20. 20.
    P. Gepner, Immunotolerance du RU 41740. Presse Med. 17:1458–1460 (1988).PubMedGoogle Scholar
  21. 21.
    C. Griscelli, B. Rospierre, J. Montreuil, B. Fournet, G. Bruvier, J. M. Lang, C. Marchiani, R. Zalisz, and R. Edelstein, Pouvoir immunomodulateur de glycoproteines isolees de Klebsiella pneumoniae. In: Immunomodulation by microbial products and related compounds. Y. Yamamura and S. Kotani, ed., Proc. of an Internatl. Symp., Osaka, July 27–29, 1981, Amsterdam, Oxford, Princeton, Excerpta Medica 563:261–265 (1982).Google Scholar
  22. 22.
    M. Guenounou, F. Vacheron, R. Zalisz, P. Smets, and J. Agneray, Immunological activities of RU 41740, a glcoprotein extract from Klebsieela pneumoniae. I. Activation of murine B cells and induction of interleukin-1 production by macrophages. Ann. Immunol. (Inst. Pasteur) 135D:59–69 (1984).CrossRefGoogle Scholar
  23. 23.
    J. Herman, M. C. Kew, A. and A. R. Rabson, The effect of RU 41740 (Biostim) on the production of interleukin 1 by monocytes and enriched large granular lymphocytes in normals and patients with hepatocellular carcinoma. Cancer. Immunol. Immunother. 21a;26–30 (1986).Google Scholar
  24. 24.
    R. Fugonot, L. M. Gutierrez, and L. Hugonot, Action preventive des immunomo-dulateurs sur les infections respiratoires des sujets ages. Presse Med. 17:1445–1449 (1988).Google Scholar
  25. 25.
    V. Joly, Action d’un immunomodulateur, le RU 41740, sur les infections experimentales. Presse Med. 17:1430–1432 (1988).PubMedGoogle Scholar
  26. 26.
    C. Lambre, J. C. Almayrac, A. Boussairi, A. Greffard, H. De Cremous, K. Atassi, and J. Bignon, Retentissement de l’administration d’un extrait de paroi de klebsiella pneumoniae sur l’immunite locale pulminaire. Rev. Mal. Resp. 6:R154–R194 (1989).Google Scholar
  27. 27.
    J. M. Lang, J. A. Gastaut, J. J. Sotto, J. Troncy, C. Marchiani, Enhancement of delayed cutaneous hypersensitivity by oral administration of RU 41740 (Biostim) in lymphoma patients. A randomized double blind multicentric trial. Int. J. Immunopharma. 8:687–690 (1986).CrossRefGoogle Scholar
  28. 28.
    G. Lenoir, Mucoviscidose. Encycl. Med. Chir (Paris-France) Poumons 6039 A95 9_188: 1-22.Google Scholar
  29. 29.
    F. Neukirch et al, La bronchite chronique. Rev. Mal. Resp. 5:331–346 (1988).Google Scholar
  30. 30.
    H. Nielsen, and J. Bonde, Association of defective monocyte chemotaxis with recurrent acute exacerbations in chronic obstructive lung disease. Eur. J. Respir. Dis. 68:200–206 (1986).PubMedGoogle Scholar
  31. 31.
    Y. Pacheco, P. Fonlupt, M. Dubois, N. Biot, M. Perrin-Fayolle, and H. Pacheco, La methylation des phospholipides membranes du macrophage alveolaire dans la sarcoidose pulmonaire et les fibroses pulmonaires interstitielles diffuses. Pathol. Bio., 34,10:1067–1073 (1986).Google Scholar
  32. 32.
    M. L. Profeta, P. L. Meroni, G. Guidi, R. Palmieri, G. Palladino, V. Cantone, and C. Zanussi, Influenza vaccination with adjuvant RU 41740 in the elderly. Lancet April 25, 8539 1:973 (1987).CrossRefGoogle Scholar
  33. 33.
    A. Rudent, R. Zalisz, A. M. Quero, and P. Smets, Enhanced resistance of mice against influenza virus infection after local administration of glycoprotein extracts from klebsieela pneumoniae. In: J. Immunopharmacol. 7,4, 525–531 (1989).CrossRefGoogle Scholar
  34. 34.
    S. Sozzani, W. Luini, L. Braceschi, and F. Spreafico, The effect ofBiostim (RU 41740) on natural killer activity in different mouse organes. Int. J. Immuno-pharmacol. 8(8):845–853 (1986).CrossRefGoogle Scholar
  35. 35.
    F. Spreafico, Problems and challenges in the use of immunomodulating agents. Int. Arch. Allergy Appl. Immunol. 76, suppl. 1:108–111 (1985).PubMedCrossRefGoogle Scholar
  36. 36.
    J. R. Viallat, C. Boutin, P. Farisse, and D. Constantini, Etude en double aveugle d’un immunomodulateur d’origin bacterienne (Biostim) dans la prevention des episodes infectieux chez le bronchitique chronique. Poumon Coeur 39:53–57 (1983).PubMedGoogle Scholar
  37. 37.
    C. Wood, and G. Moller, Influence of RU 41740, a glcoprotein extract from klebsielle pneumoniae, on the murine immune system. KK. II. RU 41740 facilitates the responses to Con A in otherwise unresponsive T. enriched cells. J. Immunol. 125(1):131–136 (1985).Google Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • I. Ounis
    • 1
  1. 1.CASSENNE LaboratoriesTour Roussel Hoechst 1 Terrasse BelliniPuteauxFrance

Personalised recommendations